{"id":567010,"date":"2021-10-01T18:34:02","date_gmt":"2021-10-01T18:34:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=567010"},"modified":"2021-10-01T18:34:02","modified_gmt":"2021-10-01T18:34:02","slug":"nonhodgkins-lymphoma-pipeline-industry-analysis-drugs-pipeline-treatment-and-key-companies-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/nonhodgkins-lymphoma-pipeline-industry-analysis-drugs-pipeline-treatment-and-key-companies-by-delveinsight_567010.html","title":{"rendered":"Non-Hodgkin’s Lymphoma Pipeline: Industry Analysis, Drugs, Pipeline, Treatment and Key Companies by DelveInsight"},"content":{"rendered":"
\n
\"Non-Hodgkin's<\/a><\/div>\n
\n
Non-Hodgkin’s Lymphoma Pipeline<\/div>\n<\/div>\n<\/div>\n

Non-Hodgkin’s Lymphoma<\/strong> (NHL) is a cancer of the lymphatic system that develops from lymphocytes. Non-Hodgkin lymphoma can be further subdivided into more than 30 types depending on the type of lymphocyte involved: B lymphocytes (B cells) or T lymphocytes (T cells). They can be further labeled as either aggressive (fast-growing) or indolent (slow-growing).<\/p>\n

 <\/p>\n

DelveInsight’s ‘<\/strong>Non-Hodgkin’s Lymphoma (NHL) Pipeline Insights<\/strong><\/a>’<\/strong> report lays down a holistic coverage of the available therapies, Non-Hodgkin’s Lymphoma pipeline therapies in different phases of clinical development, key companies active in the NHL pipeline domain, drivers and barriers in the successful launch of the therapies and future trends. <\/p>\n

 <\/p>\n

Some of the notable pointers extracted from the Non-Hodgkin’s Lymphoma Pipeline<\/a> report:<\/strong><\/p>\n